Author:
Babb Jessica A.,Constantino Nicholas J.,Kaplan Gary B.,Chartoff Elena H.
Abstract
AbstractOxycodone is one of the most widely prescribed and misused opioid painkillers in the United States. Evidence suggests that biological sex and hormonal status can impact drug reward in humans and rodents, but the extent to which these factors can influence the rewarding effects of oxycodone is unclear. The purpose of this study was to utilize place conditioning to determine the effects of sex and female hormonal status on the expression of oxycodone conditioned reward in rats. Gonadally intact adult Sprague-Dawley male and female rats were used to test: (1) whether both sexes express conditioned reward to oxycodone at similar doses, (2) the impact of conditioning session length on oxycodone conditioned reward expression in both sexes, and (3) the influence of female estrous cycle stage on oxycodone conditioned reward expression. Both sexes expressed conditioned reward at the same doses of oxycodone. Increasing the length of conditioning sessions did not reveal an effect of sex and resulted in lower magnitude conditioned reward expression. Importantly however, female stage of estrous cycle significantly influenced oxycodone conditioned reward expression. These results suggest that female hormonal status can impact the rewarding effects of opioids and thus have important implications for prescription opioid treatment practices.
Funder
U.S. Department of Veterans Affairs
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21-07-01-003, NSDUH Series H-56) https://www.samhsa.gov/data (2021).
2. Marsh, J. C., Park, K., Lin, Y.-A. & Bersamira, C. Gender differences in trends for heroin use and nonmedical prescription opioid use, 2007–2014. J. Subst. Abus. Treat. 87, 79–85 (2018).
3. Simoni-Wastila, L., Ritter, G. & Strickler, G. Gender and other factors associated with the nonmedical use of abusable prescription drugs. Subst. Use Misuse 39, 1–23 (2004).
4. Back, S. E. et al. Prescription opioid aberrant behaviors: A pilot study of gender differences. Clin. J. Pain 25, 477–484 (2009).
5. Cicero, T. J., Ellis, M. S., Surratt, H. L. & Kurtz, S. P. The changing face of heroin use in the United States: A retrospective analysis of the past 50 years. JAMA Psychiatry 71, 821–826 (2014).